Key result
In patients with advanced angiosarcoma, a cutaneous primary tumor site was associated with a better overall survival compared to a visceral primary site.
Why the study?
Angiosarcoma is a rare disease with a dismal prognosis, and the treatment landscape and prognostic factors for advanced disease remain elusive.
Observational (n=276)
Yes
Advanced angiosarcoma in Asia has a poor prognosis with a median overall survival of 7.8 months, and age >65, male gender, and non-cutaneous primary sites are associated with worse outcomes.
Answers are grounded in this paper and cite their sources.
Supports prognostic stratification by primary site in advanced angiosarcoma; leaves open site-specific therapeutic implications for prospective validation.
Angiosarcoma (AS) is a rare disease with a dismal prognosis. The treatment landscape and prognostic factors for advanced AS, including locally advanced, unresectable, and metastatic disease remain elusive. The Asian Sarcoma Consortium is an international collaborative effort to understand the sarcoma treatment landscape in Asia. We undertook a retrospective chart review of AS patients seen in 8 sarcoma academic centers across Asia. Patients with complete clinical, treatment, and follow-up data were enrolled. Overall, 276 advanced AS patients were included into this study; 84 (30%) of the patients had metachronous metastatic AS. The median age was 67 y; primary sites of AS was cutaneous in 55% and visceral in 45% of patients. In total, 143 (52%) patients received at least 1 line of systemic chemotherapy. The most common first-line chemotherapy regimen used was paclitaxel (47.6%) followed by liposomal doxorubicin (19.6%). The median overall survival (OS) was 7.8 mo. Significant prognostic factors for OS included age > 65 (hazard ratio (HR) 1.54, P = .006), male gender (HR 1.39, P = .02), and a cutaneous primary AS site (HR 0.63, P = .004). The median progression-free survival (PFS) for first-line chemotherapy was 3.4 mo. PFS for single vs combination or paclitaxel vs liposomal doxorubicin chemotherapy regimens were comparable. This study provides an insight into the treatment patterns and prognostic factors of advanced AS patients in Asia. Prognosis of advanced AS remains poor. Data from this study serve as a benchmark for future clinical study design.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2021) conducted an observational in Advanced angiosarcoma (n=276). Cutaneous primary tumor site vs. Visceral primary tumor site was evaluated on Overall survival (HR 0.63, 95% CI 0.46-0.86, p=0.004). In patients with advanced angiosarcoma, a cutaneous primary tumor site was associated with a better overall survival compared to a visceral primary site.
Synapse has enriched 10 related papers. Consider them for comparative context: